Tarsus Pharmaceuticals (TARS) Other financing activities (2020 - 2026)

Tarsus Pharmaceuticals' Other financing activities history runs 7 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Other financing activities fell 16.21% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $2.1 million (down 13.42% YoY), while the FY2025 annual figure was $2.3 million, up 30.19% from the prior year.
• Other financing activities for Q1 2026 stood at $1.2 million, down from $1.2 million in the prior quarter.
• The five-year high for Other financing activities was $8.6 million in Q2 2024, with the low at -$6.0 million in Q3 2024.
• The 5-year median for Other financing activities is $222000.0 (2022), against an average of $456000.0.
• The sharpest annual moves came in 2022 and 2024: Other financing activities surged 1268.42% in 2022, then plunged 1395.48% in 2024.
• Tarsus Pharmaceuticals' Other financing activities stood at -$99000.0 in 2022, then surged by 228.28% to $127000.0 in 2023, then slumped by 1317.32% to -$1.5 million in 2024, then surged by 179.95% to $1.2 million in 2025, then retreated by 2.59% to $1.2 million in 2026.
• Business Quant data shows TARS's Other financing activities at $1.2 million in Q1 2026, $1.2 million in Q4 2025, and -$336000.0 in Q2 2025.